S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)

Kura Oncology (KURA) Stock Price, News & Analysis

$21.60
+0.43 (+2.03%)
(As of 03:16 PM ET)
Today's Range
$20.89
$21.65
50-Day Range
$13.42
$23.53
52-Week Range
$7.41
$24.17
Volume
257,237 shs
Average Volume
1.47 million shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.28

Kura Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
31.2% Upside
$28.28 Price Target
Short Interest
Healthy
16.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
1.89mentions of Kura Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.35) to ($2.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

194th out of 938 stocks

Pharmaceutical Preparations Industry

79th out of 433 stocks

KURA stock logo

About Kura Oncology Stock (NASDAQ:KURA)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

KURA Stock Price History

KURA Stock News Headlines

Stifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
KURA Jul 2024 22.500 call
TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)
Q4 2023 Kura Oncology Inc Earnings Call
KURA Mar 2024 25.000 call
KURA Mar 2024 22.500 put
KURA Mar 2024 30.000 call
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.28
High Stock Price Target
$37.00
Low Stock Price Target
$10.50
Potential Upside/Downside
+31.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-152,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.35 per share

Miscellaneous

Free Float
72,026,000
Market Cap
$1.64 billion
Optionable
Optionable
Beta
0.86
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 55)
    Ph.D., Chairman, CEO & President
    Comp: $1.06M
  • Ms. Kathleen Ford (Age 77)
    Chief Operating Officer
    Comp: $754.24k
  • Dr. Stephen Dale M.D. (Age 52)
    Chief Medical Officer
    Comp: $684.41k
  • Mr. Thomas Doyle (Age 53)
    Senior Vice President of Finance & Accounting
  • Mr. Pete De Spain
    Executive Vice President of Investor Relations & Corporate Communications
  • Ms. Teresa Brophy Bair Esq. (Age 53)
    J.D., Chief Legal Officer & Corporate Secretary
  • Dr. Roger Bakale Ph.D.
    Senior Vice President of Manufacturing & Supply Chain
  • Ms. Maureen Clancy M.B.A.
    VP and Global Head of Program Leadership & Project Management
  • Dr. Mollie Leoni M.D.
    Executive Vice President of Clinical Development
  • Mr. Brian T. Powl M.B.A. (Age 50)
    M.S., Chief Commercial Officer

KURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price target for 2024?

8 equities research analysts have issued twelve-month target prices for Kura Oncology's stock. Their KURA share price targets range from $10.50 to $37.00. On average, they anticipate the company's stock price to reach $28.28 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2024?

Kura Oncology's stock was trading at $14.38 at the beginning of 2024. Since then, KURA shares have increased by 49.9% and is now trading at $21.55.
View the best growth stocks for 2024 here
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our KURA earnings forecast
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same quarter in the prior year, the firm posted ($0.49) EPS.

What ETF holds Kura Oncology's stock?

Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.68%), Vanguard Group Inc. (5.30%), Vanguard Group Inc. (5.30%), Armistice Capital LLC (2.99%), Dimensional Fund Advisors LP (2.70%) and Franklin Resources Inc. (1.82%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KURA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners